Table 2.
Clinician-reported Patient Clinical Characteristics
| Characteristic | Total (N = 25) | IG (N = 15) | DG (N = 10) |
|---|---|---|---|
| Time in clinician’s practice (years) | |||
| Mean (SD) | 2.7 (3.7) | 0.9 (1.2) | 5.3 (4.5) |
| Range (Min, Max) | (0.1, 13.6) | (0.1, 4.2) | (0.5, 13.6) |
| Duration of diagnosis (years) | |||
| Mean (SD) | 1.7 (1.8) | 1.7 (2.0) | 1.8 (1.6) |
| Range (Min, Max) | (0.2, 7.0) | (0.2, 7.0) | (0.4, 4.8) |
| Current medications for gastroparesis, n (%)a | |||
| Gastric antisecretory agent | 11 (44.0%) | 7 (46.7%) | 4 (40.0%) |
| Prokinetic agent | 9 (36.0%) | 6 (40.0%) | 3 (30.0%) |
| Antiemetic agent | 9 (36.0%) | 7 (46.7%) | 2 (20.0%) |
| Diabetes medical treatment | 7 (28.0%) | 0 (0.0%) | 7 (70.0%) |
| Pain medications | 5 (20.0%) | 5 (33.3%) | 0 (0.0%) |
| Psychotropic agent | 4 (16.0%) | 3 (20.0%) | 1 (10.0%) |
| Gastric electric stimulation (pacemaker) | 1 (4.0%) | 0 (0.0%) | 1 (10.0%) |
| Otherb | 4 (16.0%) | 4 (26.7%) | 0 (0.0%) |
| Prior GI specific surgeries, n (%) | |||
| Gastric electric stimulation (GES) | 1 (4.0%) | 0 (0.0%) | 1 (10.0%) |
| Otherc | 3 (12.0%) | 2 (13.3%) | 1 (10.0%) |
| None | 21 (84.0%) | 13 (86.7%) | 8 (80.0%) |
| Time since most recent upper endoscopy (years) | |||
| Mean (SD) | 1.2 (1.5) | 1.2 (1.6) | 1.2 (1.2) |
| Range (Min, Max) | (0.0, 5.9) | (0.1, 5.9) | (0.0, 3.3) |
| Physician rating of gastroparesis severity, n (%) | |||
| None | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Very mild | 3 (12.0%) | 1 (6.7%) | 2 (20.0%) |
| Mild | 10 (40.0%) | 4 (26.7%) | 6 (60.0%) |
| Moderate | 9 (36.0%) | 7 (46.7%) | 2 (20.0%) |
| Severe | 3 (12.0%) | 3 (20.0%) | 0 (0.0%) |
| Very severe | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
| Comorbid conditions, n (%)a | |||
| Obesity | 8 (32.0%) | 4 (26.7%) | 4 (40.0%) |
| Other gastrointestinal disorder (other than gastroparesis)d | 7 (28.0%) | 4 (26.7%) | 3 (30.0%) |
| Mood disorder or mental health condition | 4 (16.0%) | 3 (20.0%) | 1 (10.0%) |
| Insomnia/sleep problems | 4 (16.0%) | 4 (26.7%) | 0 (0.0%) |
| Respiratory condition | 4 (16.0%) | 3 (20.0%) | 1 (10.0%) |
| Cardiovascular condition | 3 (12.0%) | 1 (6.7%) | 2 (20.0%) |
| Dyslipedemia/hyperlipidemia | 3 (12.0%) | 0 (0.0%) | 3 (30.0%) |
| Neurological condition | 1 (4.0%) | 0 (0.0%) | 1 (10.0%) |
| Otherd | 4 (16.0%) | 3 (20.0%) | 1 (10.0%) |
| None | 3 (12.0%) | 2 (13.3%) | 1 (10.0%) |
aNot mutually exclusive
bOther treatment: Azithromycin, Metoclopramide, Lansoprazole; Botox injection of pyloris; Linaclotide; nasojejunal (NJ) tube, Pantoprazole
cOther GI surgery: Cholecystectomy
dOther co-morbidity: Fibromyalgia, Iron Deficiency Anemia, Iron Deficiency Anemia, Lyme Disease; Fibromyalgia, Chronic fatigue syndrome, Postural orthostatic tachycardia syndrome (POTS)